Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland.
Finnish Centre for Evidence-Based Health Care: A JBI Centre of Excellence, Helsinki, Finland.
JBI Evid Synth. 2022 Dec 1;20(12):3058-3066. doi: 10.11124/JBIES-21-00460.
The objective of this review is to provide an overview of adverse drug events in cost-effectiveness analyses related to the pharmacological treatments of diabetes and diabetes-related complications.
The inclusion of adverse drug events in cost-effectiveness analyses is recognized in health technology assessments guidelines, but in practice, this is inconsistent. This inconsistency may affect the reliability of the evaluation and, therefore, indicate that the information provided for decision-making in health care is misleading. Reviewing if and how adverse drug events are incorporated in cost-effectiveness analyses is necessary to address this gap.
Studies including participants who are receiving pharmacological interventions for diabetes, diabetic retinopathy, or diabetic macular edema will be considered for inclusion. We will include sources that focus on cost-effectiveness analyses using modeling framework, and are published in English between 2011 and the present. Other types of analyses and other types of conditions will be excluded.
The information sources to be searched include MEDLINE, CINAHL, Scopus, Web of Science, the NHS Economic Evaluations Database, and the Health Technology Assessment Database. Studies in English will be considered for inclusion in the review. Potential sources will be assessed by 2 independent reviewers and imported into the JBI System for the Unified Management, Assessment and Review of Information. The results of the search and the study inclusion process will be reported in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. A specific data extraction form will be used to extract and analyze the data. Results will be presented in tabular and graphic formats with a narrative summary, and will be discussed in the context of current literature and guidelines.
本次综述的目的在于概述与糖尿病及其相关并发症的药物治疗相关的药物不良事件在成本效益分析中的情况。
药物不良事件纳入成本效益分析已在健康技术评估指南中得到认可，但在实践中，这种做法并不一致。这种不一致性可能会影响评估的可靠性，因此表明为医疗保健决策提供的信息具有误导性。有必要对药物不良事件是否以及如何纳入成本效益分析进行审查，以解决这一差距。
将纳入正在接受药物干预的糖尿病、糖尿病性视网膜病变或糖尿病性黄斑水肿患者的研究。我们将纳入关注使用建模框架进行成本效益分析的资源，且这些资源发表于 2011 年至目前的英文期刊。其他类型的分析和其他类型的疾病将被排除在外。
待搜索的信息来源包括 MEDLINE、CINAHL、Scopus、Web of Science、NHS 经济评估数据库和卫生技术评估数据库。将考虑纳入符合条件的英语研究。将由 2 名独立评审员评估潜在来源，并将其导入 JBI 系统以进行信息的统一管理、评估和审查。将按照系统评价和荟萃分析的首选报告项目报告检索和研究纳入过程的结果。将使用特定的数据提取表格来提取和分析数据。结果将以表格和图形格式呈现，并附有叙述性总结，并将根据当前文献和指南进行讨论。
